GSK Flonase suit
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has dropped its lawsuit disputing FDA's approval of generic Flonase (fluticasone propionate). GSK decided not to appeal the March 6 ruling of Baltimore federal court Judge Andre Davis that denied the firm's request for a preliminary injunction on the sale of the generic nasal spray. FDA's approval of the generic nasal spray Feb. 22 prompted GSK to file suit; the court granted the firm a temporary restraining order suspending FDA approval of the drug until March 6 (1"The Tan Sheet" Feb. 27, 2006, p. 4). GSK discontinued plans for an Rx-to-OTC switch of Flonase in favor of pursuing legal action against the sale of generics, and now says it has no plans to resume a switch program...
You may also be interested in...
Flonase Generic Launch Blocked; Glaxo Drops Switch Plan
GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.